Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

Khoo, T; Gao, Lan

File(s) under permanent embargo

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

journal contribution

posted on 2021-01-01, 00:00 authored by T Khoo, Lan GaoLan Gao

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

History

Journal

Expert Review of Pharmacoeconomics and Outcomes Research

Volume

21

Issue

3

Pagination

415 - 423

Publisher

TAYLOR & FRANCIS LTD

Location

England

Publisher DOI

https://doi.org/10.1080/14737167.2021.1847648

ISSN

1473-7167

eISSN

1744-8379

Language

English

Author URL

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000596294300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a045e4b2bb1f2b747c68c720ec8913b7

Publication classification

C1 Refereed article in a scholarly journal

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Health Care Sciences & Services Health Policy & Services Pharmacology & Pharmacy Osimertinib non-small cell lung cancer EGFR mutation economic evaluation cost-effectiveness

Licence

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

File(s) under permanent embargo

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

History

Journal

Volume

Issue

Pagination

Publisher

Location

Publisher DOI

ISSN

eISSN

Language

Author URL

Publication classification

Usage metrics

Categories

Keywords

Licence

Exports